# US 11,110,065 B2 · Sintered ferrous amino acid particles and use of the same against a virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,065 B2
- Document ID: US11110065B2
- Status: Granted
- Kind: B2
- Application number: 16/223,426
- Filed: 2018-12-18
- Published: 2019-09-12
- Granted: 2021-09-07
- Earliest claimed: 2018-03-06
- Assignees: Profeat Biotechnology Co., Ltd.
- Applicants: Profeat Biotechnology Co., Ltd.
- Inventors: Tsun-Yuan Lin; Mu-Kuei Chen; Kai-Ting Wang; Hsun-Jin Jan
- Web page: https://patentgrep.com/patent/US11110065B2

## CPC

- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 31/295: Iron group metal compounds
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition includes sintered ferrous amino acid particles prepared by sintering a ferrous amino acid chelate which includes ferrous ions and an amino acid. The sintered ferrous amino acid particles have an average particle size ranging from 500 to 2600 nm and a weight average molecular weight ranging from 1,500 Dalton to 600,000 Dalton. Also disclosed herein are a method for inhibiting and/or killing a virus in a subject and applications of such method. The method includes administering to the subject the composition.

## Claims

### Claim 1

A composition comprising sintered ferrous amino acid particles prepared by sintering a ferrous amino acid chelate, the ferrous amino acid chelate including a ferrous ion and an amino acid, and the sintered ferrous amino acid particles having an average particle size ranging from 500 to 2600 nm and a weight average molecular weight ranging from 1,500 Dalton to 600,000 Dalton.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the sintered ferrous amino acid particles have a weight average molecular weight ranging from 400,000 Dalton to 600,000 Dalton.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the ferrous amino acid chelate is a ferrous glycinate chelate.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the ratio of the ferrous ion to the amino acid in the ferrous amino acid chelate ranges from 1:1 to 1:4.

### Claim 5 (depends on 1)

A method for inhibiting a virus in a subject in need thereof, the method comprising:
administering a therapeutically effective amount of the composition of claim 1 to the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein the composition is orally administered.

### Claim 7 (depends on 5)

The method of claim 5, wherein the composition is a pharmaceutical composition.

### Claim 8 (depends on 5)

The method of claim 5, wherein the virus is selected from the group consisting of porcine epidemic diarrhea virus, porcine respiratory and reproductive syndrome virus, swine influenza virus, and combinations thereof.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the ferrous amino acid chelate is prepared by mixing the ferrous ion and the amino acid, followed by heating from 60° C. to 90° C. for 8 hours to 48 hours, and sintering the ferrous amino acid chelate is conducted at a temperature of 240° C. to 260° C.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the ferrous amino acid chelate consists of the ferrous ion and the amino acid.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the ferrous amino acid chelate is sintered at a temperature ranging from 200° C. to 240° C.